The outpatient prescription market for flu drugs has recovered. Their prescription market, which had remained almost nonexistent for 3 years after the COVID-19 pandemic, has expanded significantly since then. With the flu epidemic lasting more than a year, the market for flu treatments has returned to pre-pandemic levels.

According to the market research institution UBIST, the outpatient prescription market for influenza (flu) totaled KRW 6.8 billion in Q1, up 34.8% YoY. The prescription market for flu medications has grown more than 160 times in 2 years from just KRW 40 million in Q1 2022.

The flu drug market has undergone significant changes throughout the COVID-19 pandemic and